SG11201908786VA - Substituted indoline derivatives as dengue viral replication inhibitors - Google Patents

Substituted indoline derivatives as dengue viral replication inhibitors

Info

Publication number
SG11201908786VA
SG11201908786VA SG11201908786VA SG11201908786VA SG 11201908786V A SG11201908786V A SG 11201908786VA SG 11201908786V A SG11201908786V A SG 11201908786VA SG 11201908786V A SG11201908786V A SG 11201908786VA
Authority
SG
Singapore
Prior art keywords
international
leuven
dengue viral
turnhoutseweg
beerse
Prior art date
Application number
Other languages
English (en)
Inventor
Bart Rudolf Romanie Kesteleyn
Jean-François Bonfanti
Erwin Coesemans
Pierre Jean-Marie Bernard Raboisson
Arnaud Didier M Marchand
Dorothée Alice Marie-Eve Bardiot
Original Assignee
Janssen Pharmaceuticals Inc
Univ Leuven Kath
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceuticals Inc, Univ Leuven Kath filed Critical Janssen Pharmaceuticals Inc
Publication of SG11201908786VA publication Critical patent/SG11201908786VA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41961,2,4-Triazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SG11201908786V 2017-03-31 2018-03-29 Substituted indoline derivatives as dengue viral replication inhibitors SG11201908786VA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17164048 2017-03-31
PCT/EP2018/058079 WO2018178240A1 (en) 2017-03-31 2018-03-29 Substituted indoline derivatives as dengue viral replication inhibitors

Publications (1)

Publication Number Publication Date
SG11201908786VA true SG11201908786VA (en) 2019-10-30

Family

ID=58464340

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201908786V SG11201908786VA (en) 2017-03-31 2018-03-29 Substituted indoline derivatives as dengue viral replication inhibitors

Country Status (32)

Country Link
US (1) US11083707B2 (da)
EP (1) EP3601266B1 (da)
JP (1) JP7203752B2 (da)
KR (1) KR102530832B1 (da)
CN (1) CN110461831B (da)
AR (1) AR111314A1 (da)
AU (1) AU2018246301B2 (da)
BR (1) BR112019020175A2 (da)
CA (1) CA3055867C (da)
CL (1) CL2019002745A1 (da)
CO (1) CO2019010295A2 (da)
CR (1) CR20190446A (da)
DK (1) DK3601266T3 (da)
EA (1) EA039784B1 (da)
EC (1) ECSP19070369A (da)
ES (1) ES2884151T3 (da)
HR (1) HRP20210942T1 (da)
HU (1) HUE054678T2 (da)
IL (1) IL269658B (da)
JO (1) JOP20180025B1 (da)
LT (1) LT3601266T (da)
MX (1) MX2019011606A (da)
NI (1) NI201900099A (da)
PE (1) PE20191650A1 (da)
PH (1) PH12019502201A1 (da)
SG (1) SG11201908786VA (da)
SI (1) SI3601266T1 (da)
TW (1) TWI795393B (da)
UA (1) UA126288C2 (da)
UY (1) UY37645A (da)
WO (1) WO2018178240A1 (da)
ZA (1) ZA201906395B (da)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201116559D0 (en) 2011-09-26 2011-11-09 Univ Leuven Kath Novel viral replication inhibitors
JOP20160086B1 (ar) 2015-05-08 2021-08-17 2 Katholieke Univ Leuven Ku Leuven Research And Development مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JOP20160198B1 (ar) 2015-09-16 2022-03-14 Janssen Pharmaceuticals Inc مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JO3633B1 (ar) 2015-09-16 2020-08-27 Katholieke Univ Leuven Ku Leuven Research & Development مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
KR102359735B1 (ko) 2016-03-31 2022-02-08 얀센 파마슈티칼즈, 인코포레이티드 뎅기 바이러스 복제 억제제로서의 치환 인돌린 유도체
US10646469B2 (en) 2016-03-31 2020-05-12 Janssen Pharmaceuticals, Inc. Substituted indole derivatives as dengue viral replication inhibitors
EP3436004A1 (en) 2016-04-01 2019-02-06 Janssen Pharmaceuticals, Inc. Substituted indole compound derivatives as dengue viral replication inhibitors
JOP20170069B1 (ar) 2016-04-01 2021-08-17 1 Janssen Pharmaceuticals Inc مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JOP20180025B1 (ar) 2017-03-31 2021-08-17 Janssen Pharmaceuticals Inc مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JOP20180026A1 (ar) * 2017-03-31 2019-01-30 Univ Leuven Kath مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
TWI771420B (zh) 2017-05-22 2022-07-21 美商健生醫藥公司 作為登革熱病毒複製抑制劑之經取代之吲哚啉衍生物(一)
JP7203764B2 (ja) 2017-05-22 2023-01-13 ヤンセン ファーマシューティカルズ,インコーポレーテッド デングウイルス複製阻害剤としての置換インドリン誘導体
CN109485596A (zh) * 2018-12-19 2019-03-19 山东理工职业学院 一种含吲哚啉的登革病毒抑制剂的制备方法
CN112159325B (zh) * 2020-10-10 2022-11-25 浙江工业大学 一种合成2-氨基-3-硝基甲苯的方法

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69830335T2 (de) 1997-10-27 2006-02-02 Eli Lilly And Co., Indianapolis MORPHOLINO-N-ETHYL ESTER PRODROGEN VON INDOL sPLA 2 HEMMER
GB0110832D0 (en) 2001-05-03 2001-06-27 Virogen Ltd Antiviral compounds
WO2003050295A2 (en) 2001-12-12 2003-06-19 Conforma Therapeutics Corporation Assays and implements for determining and modulating hsp90 binding activity
GB0215293D0 (en) 2002-07-03 2002-08-14 Rega Foundation Viral inhibitors
WO2005113516A1 (en) 2004-05-14 2005-12-01 Neurocrine Biosciences, Inc. Uracil-type gonadotropin-releasing hormone receptor antagonists and methods related thereto
MX2007008587A (es) 2005-01-14 2007-09-07 Genelabs Tech Inc Derivados de indol para tratamiento de infecciones virales.
KR20070102741A (ko) 2005-02-09 2007-10-19 미게닉스 인코포레이티드 플라비비리대 감염증을 치료하거나 예방하기 위한 조성물및 방법
EP2293671A4 (en) 2008-06-03 2012-03-21 Siga Technologies Inc SMALL MOLECULAR INHIBITORS FOR TREATING OR PREVENTING DENGUE INFECTIONS
US8143259B2 (en) 2008-08-19 2012-03-27 Janssen Pharmaceutica, Nv Cold menthol receptor antagonists
TWI453207B (zh) 2008-09-08 2014-09-21 Signal Pharm Llc 胺基三唑并吡啶,其組合物及使用其之治療方法
WO2010091413A1 (en) 2009-02-09 2010-08-12 Enanta Pharmaceuticals, Inc. Linked dibenzimidazole derivatives
GB0910003D0 (en) 2009-06-11 2009-07-22 Univ Leuven Kath Novel compounds for the treatment of neurodegenerative diseases
US8993604B2 (en) 2009-06-30 2015-03-31 Siga Technologies, Inc. Treatment and prevention of dengue virus infections
US7948798B1 (en) 2009-07-22 2011-05-24 Marvell International Ltd. Mixed multi-level cell and single level cell storage device
ES2543105T3 (es) 2010-01-15 2015-08-14 Gilead Sciences, Inc. Inhibidores de virus flaviviridae
WO2011120025A1 (en) 2010-03-26 2011-09-29 Glaxo Group Limited Indazolyl-pyrimidines as kinase inhibitors
JP5716205B2 (ja) 2011-03-29 2015-05-13 学校法人日本大学 グルコシダーゼ活性阻害用組成物及びそのスクリーニング方法
GB201116559D0 (en) * 2011-09-26 2011-11-09 Univ Leuven Kath Novel viral replication inhibitors
GB201305376D0 (en) 2013-03-25 2013-05-08 Univ Leuven Kath Novel viral replication inhibitors
AP2016009122A0 (en) 2013-10-23 2016-03-31 Janssen Sciences Ireland Uc Carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
DK3099687T3 (da) 2014-01-31 2018-10-22 Bristol Myers Squibb Co Makrocykler med heterocykliske p2'-grupper som faktor xia-hæmmere
UA121119C2 (uk) 2014-10-01 2020-04-10 Янссен Фармасьютикалз, Інк. Похідні моно- або дизаміщених індолів як інгібітори реплікації вірусів денге
NO2721243T3 (da) 2014-10-01 2018-10-20
JP6701185B2 (ja) 2014-10-01 2020-05-27 ヤンセン ファーマシューティカルズ,インコーポレーテッド デングウィルス複製阻害剤としての一または二置換インドール
JOP20150335B1 (ar) 2015-01-16 2022-03-14 Janssen Pharmaceuticals Inc مشتقات اندول بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
AR103680A1 (es) 2015-02-23 2017-05-24 Lilly Co Eli Inhibidores selectivos de bace1
JOP20160086B1 (ar) 2015-05-08 2021-08-17 2 Katholieke Univ Leuven Ku Leuven Research And Development مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JOP20160198B1 (ar) * 2015-09-16 2022-03-14 Janssen Pharmaceuticals Inc مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JO3633B1 (ar) 2015-09-16 2020-08-27 Katholieke Univ Leuven Ku Leuven Research & Development مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
MX2018005547A (es) 2015-11-03 2018-11-09 Zoetis Services Llc Compuestos polimericos sol-gel y sus usos.
CA3019298C (en) 2016-03-31 2023-08-29 Takeda Pharmaceutical Company Limited Heterocyclic compound
KR102359735B1 (ko) 2016-03-31 2022-02-08 얀센 파마슈티칼즈, 인코포레이티드 뎅기 바이러스 복제 억제제로서의 치환 인돌린 유도체
US10646469B2 (en) 2016-03-31 2020-05-12 Janssen Pharmaceuticals, Inc. Substituted indole derivatives as dengue viral replication inhibitors
EP3436018A4 (en) 2016-04-01 2019-11-13 Signal Pharmaceuticals, LLC SUBSTITUTED AMINOPURINE COMPOUNDS, COMPOSITIONS AND METHOD FOR TREATING THEREOF
KR102411744B1 (ko) 2016-04-01 2022-06-21 바스프 에스이 바이시클릭 화합물
JOP20170069B1 (ar) 2016-04-01 2021-08-17 1 Janssen Pharmaceuticals Inc مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
CA3019655A1 (en) 2016-04-01 2017-10-05 Amgen Inc. Chimeric receptors to flt3 and methods of use thereof
EP3436004A1 (en) 2016-04-01 2019-02-06 Janssen Pharmaceuticals, Inc. Substituted indole compound derivatives as dengue viral replication inhibitors
MX2018012019A (es) 2016-04-01 2019-07-10 Kite Pharma Inc Receptores quimericos y metodos de uso de los mismos.
AU2017240667C1 (en) 2016-04-01 2022-11-24 Kite Pharma, Inc. Chimeric antigen and T cell receptors and methods of use
JOP20180025B1 (ar) 2017-03-31 2021-08-17 Janssen Pharmaceuticals Inc مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JOP20180026A1 (ar) 2017-03-31 2019-01-30 Univ Leuven Kath مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
TWI771420B (zh) 2017-05-22 2022-07-21 美商健生醫藥公司 作為登革熱病毒複製抑制劑之經取代之吲哚啉衍生物(一)
JP7203764B2 (ja) 2017-05-22 2023-01-13 ヤンセン ファーマシューティカルズ,インコーポレーテッド デングウイルス複製阻害剤としての置換インドリン誘導体

Also Published As

Publication number Publication date
PE20191650A1 (es) 2019-11-07
MX2019011606A (es) 2019-11-08
JOP20180025B1 (ar) 2021-08-17
BR112019020175A2 (pt) 2020-06-02
AR111314A1 (es) 2019-06-26
JOP20180025A1 (ar) 2019-01-30
CO2019010295A2 (es) 2019-10-09
SI3601266T1 (sl) 2021-08-31
HRP20210942T1 (hr) 2021-10-15
JP2020512355A (ja) 2020-04-23
CL2019002745A1 (es) 2019-12-27
JP7203752B2 (ja) 2023-01-13
US20200121647A1 (en) 2020-04-23
PH12019502201A1 (en) 2020-09-28
EA039784B1 (ru) 2022-03-14
KR102530832B1 (ko) 2023-05-09
EP3601266A1 (en) 2020-02-05
IL269658A (en) 2019-11-28
HUE054678T2 (hu) 2021-09-28
CN110461831A (zh) 2019-11-15
EP3601266B1 (en) 2021-04-28
LT3601266T (lt) 2021-07-12
CN110461831B (zh) 2022-11-01
TWI795393B (zh) 2023-03-11
WO2018178240A1 (en) 2018-10-04
TW201900635A (zh) 2019-01-01
CA3055867A1 (en) 2018-10-04
IL269658B (en) 2022-01-01
CA3055867C (en) 2024-01-02
AU2018246301A1 (en) 2019-09-19
UA126288C2 (uk) 2022-09-14
NI201900099A (es) 2020-03-11
DK3601266T3 (da) 2021-07-19
CR20190446A (es) 2019-11-29
ECSP19070369A (es) 2019-10-31
US11083707B2 (en) 2021-08-10
EA201992329A1 (ru) 2020-02-20
UY37645A (es) 2018-09-28
ZA201906395B (en) 2021-05-26
ES2884151T3 (es) 2021-12-10
AU2018246301B2 (en) 2021-08-19
KR20190137108A (ko) 2019-12-10

Similar Documents

Publication Publication Date Title
SG11201908786VA (en) Substituted indoline derivatives as dengue viral replication inhibitors
SG11201908465QA (en) Substituted indoline derivatives as dengue viral replication inhibitors
SG11201808237UA (en) Substituted indole compound derivatives as dengue viral replication inhibitors
SG11201808270PA (en) Substituted indoline derivatives as dengue viral replication inhibitors
SG11201808138YA (en) Substituted indole derivatives as dengue viral replication inhibitors
SG11201909955XA (en) Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies
SG11201900163PA (en) Macrocycle kinase inhibitors
SG11201810423XA (en) Pd-1 / pd-l1 inhibitors for cancer treatment
SG11201811564QA (en) Methods of treating ovarian cancer
SG11201809912UA (en) Hybrid carriers for nucleic acid cargo
SG11201906891RA (en) Methods for the administration of certain vmat2 inhibitors
SG11201810280YA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201903155XA (en) Pharmaceutical compounds
SG11201900551WA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201900546UA (en) Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof
SG11201809751XA (en) Egfr inhibitor compounds
SG11201900443VA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201900554YA (en) Spiro-lactam nmda modulators and methods of using same
SG11201900558RA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201408318RA (en) Compositions and methods for transmucosal absorption
SG11201908517XA (en) Pyrimidinyl-pyridyloxy-naphthyl compounds and methods of treating ire1-related diseases and disorders
SG11201907804QA (en) Pharmaceutical composition comprising selexipag
SG11201906436VA (en) Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same
SG11201901534VA (en) Combination therapy with controlled-release cnp agonists
SG11201909064RA (en) Combination of an anti-pd-l1 antibody and a dna-pk inhibitor for the treatment of cancer